Sera Prognostics, Inc., was incorporated under the laws of the State of Delaware on January 17, 2008. The Company is a women's health diagnostic company that utilizes the Company's proprietary proteomics and bioinformatics platforms to discover, develop and commercialize biomarker tests with clinical significance and economic impact, with the Company's initial focus on improving pregnancy outcomes. The company's vision is to provide critical and actionable information to pregnant women, physicians and healthcare payers to significantly improve maternal and newborn health and significantly reduce healthcare costs. 

SERA

SERA Profile